Home
drive our discovery
Finch is a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.
Human-First Discovery platform
Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.
Learn morePipeline
We are advancing a rich pipeline of investigational microbiome therapeutics designed to address a wide range of unmet medical needs, with a candidate in late-stage clinical development for recurrent C. difficile infection and candidates for inflammatory bowel disease and autism spectrum disorder in pre-clinical development.
Learn moreRecent news
Finch Therapeutics to Participate in Upcoming June Investor Conferences
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Join us
Join us in our mission to transform the lives of patients and families fighting serious medical conditions.
Learn more